U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07538154) titled 'A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus' on April 12.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in participants with systemic lupus erythematosus
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus (SLE)
Intervention:
BIOLOGICAL: SCTC21C
SCTC21C will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and other appropriate doses of SCTC21C will be applied for the dose-expansion cohorts
...